91 related articles for article (PubMed ID: 15177465)
1. 2-Alkyl-4-arylimidazoles: structurally novel sodium channel modulators.
Liberatore AM; Schulz J; Pommier J; Barthelemy MA; Huchet M; Chabrier PE; Bigg D
Bioorg Med Chem Lett; 2004 Jul; 14(13):3521-3. PubMed ID: 15177465
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and SAR of 1,2-trans-(1-hydroxy-3-phenylprop-1-yl)cyclopentane carboxamide derivatives, a new class of sodium channel blockers.
Ok D; Li C; Abbadie C; Felix JP; Fisher MH; Garcia ML; Kaczorowski GJ; Lyons KA; Martin WJ; Priest BT; Smith MM; Williams BS; Wyvratt MJ; Parsons WH
Bioorg Med Chem Lett; 2006 Mar; 16(5):1358-61. PubMed ID: 16337121
[TBL] [Abstract][Full Text] [Related]
3. Butyl 2-(4-[1.1'-biphenyl]-4-yl-1H-imidazol-2-yl)ethylcarbamate, a potent sodium channel blocker for the treatment of neuropathic pain.
Liberatore AM; Schulz J; Favre-Guilmard C; Pommier J; Lannoy J; Pawlowski E; Barthelemy MA; Huchet M; Auguet M; Chabrier PE; Bigg D
Bioorg Med Chem Lett; 2007 Mar; 17(6):1746-9. PubMed ID: 17234409
[TBL] [Abstract][Full Text] [Related]
4. A structure-activity relationship study of novel phenylacetamides which are sodium channel blockers.
Roufos I; Hays S; Schwarz RD
J Med Chem; 1996 Mar; 39(7):1514-20. PubMed ID: 8691482
[TBL] [Abstract][Full Text] [Related]
5. 2,4(5)-diarylimidazoles as inhibitors of hNaV1.2 sodium channels: pharmacological evaluation and structure-property relationships.
Fantini M; Rivara M; Zuliani V; Kalmar CL; Vacondio F; Silva C; Baheti AR; Singh N; Merrick EC; Katari RS; Cocconcelli G; Ghiron C; Patel MK
Bioorg Med Chem; 2009 May; 17(10):3642-8. PubMed ID: 19394229
[TBL] [Abstract][Full Text] [Related]
6. 20(S)-protopanaxadiol and the ginsenoside Rh2 inhibit Na+ channel-activated depolarization and Na+ channel-dependent amino acid neurotransmitter release in synaptic fractions isolated from mammalian brain.
Duan Y; Nicholson RA
Comp Biochem Physiol C Toxicol Pharmacol; 2008 Apr; 147(3):351-6. PubMed ID: 18262850
[TBL] [Abstract][Full Text] [Related]
7. Functional characterization of sodium channel blockers by membrane potential measurements in cerebellar neurons: prediction of compound preference for the open/inactivated state.
Kolok S; Nagy J; Szombathelyi Z; Tarnawa I
Neurochem Int; 2006 Nov; 49(6):593-604. PubMed ID: 16777267
[TBL] [Abstract][Full Text] [Related]
8. Discovery of isoxazole voltage gated sodium channel blockers for treatment of chronic pain.
Shao PP; Ye F; Weber AE; Li X; Lyons KA; Parsons WH; Garcia ML; Priest BT; Smith MM; Felix JP; Williams BS; Kaczorowski GJ; McGowan E; Abbadie C; Martin WJ; McMasters DR; Gao YD
Bioorg Med Chem Lett; 2009 Sep; 19(18):5334-8. PubMed ID: 19683443
[TBL] [Abstract][Full Text] [Related]
9. Discovery of potent furan piperazine sodium channel blockers for treatment of neuropathic pain.
Drizin I; Gregg RJ; Scanio MJ; Shi L; Gross MF; Atkinson RN; Thomas JB; Johnson MS; Carroll WA; Marron BE; Chapman ML; Liu D; Krambis MJ; Shieh CC; Zhang X; Hernandez G; Gauvin DM; Mikusa JP; Zhu CZ; Joshi S; Honore P; Marsh KC; Roeloffs R; Werness S; Krafte DS; Jarvis MF; Faltynek CR; Kort ME
Bioorg Med Chem; 2008 Jun; 16(12):6379-86. PubMed ID: 18501613
[TBL] [Abstract][Full Text] [Related]
10. The discovery of aminopyrazines as novel, potent Na(v)1.7 antagonists: hit-to-lead identification and SAR.
Bregman H; Nguyen HN; Feric E; Ligutti J; Liu D; McDermott JS; Wilenkin B; Zou A; Huang L; Li X; McDonough SI; Dimauro EF
Bioorg Med Chem Lett; 2012 Mar; 22(5):2033-42. PubMed ID: 22306122
[TBL] [Abstract][Full Text] [Related]
11. Four novel tarantula toxins as selective modulators of voltage-gated sodium channel subtypes.
Bosmans F; Rash L; Zhu S; Diochot S; Lazdunski M; Escoubas P; Tytgat J
Mol Pharmacol; 2006 Feb; 69(2):419-29. PubMed ID: 16267209
[TBL] [Abstract][Full Text] [Related]
12. Stereospecific synthesis of "para-hydroxymexiletine" and sodium channel blocking activity evaluation.
Catalano A; Carocci A; Fracchiolla G; Franchini C; Lentini G; Tortorella V; De Luca A; De Bellis M; Desaphy JF; Conte Camerino D
Chirality; 2004 Feb; 16(2):72-8. PubMed ID: 14712469
[TBL] [Abstract][Full Text] [Related]
13. The design, preparation and SAR of novel small molecule sodium (Na(+)) channel blockers.
Ashwell MA; Lapierre JM; Kaplan A; Li J; Marr C; Yuan J
Bioorg Med Chem Lett; 2004 May; 14(9):2025-30. PubMed ID: 15080972
[TBL] [Abstract][Full Text] [Related]
14. Lithium inhibits function of voltage-dependent sodium channels and catecholamine secretion independent of glycogen synthase kinase-3 in adrenal chromaffin cells.
Yanagita T; Maruta T; Uezono Y; Satoh S; Yoshikawa N; Nemoto T; Kobayashi H; Wada A
Neuropharmacology; 2007 Dec; 53(7):881-9. PubMed ID: 17950380
[TBL] [Abstract][Full Text] [Related]
15. 2,4(5)-Diarylimidazoles: synthesis and biological evaluation of a new class of sodium channel blockers against hNa(v)1.2.
Rivara M; Baheti AR; Fantini M; Cocconcelli G; Ghiron C; Kalmar CL; Singh N; Merrick EC; Patel MK; Zuliani V
Bioorg Med Chem Lett; 2008 Oct; 18(20):5460-2. PubMed ID: 18818069
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a new class of potent inhibitors of the voltage-gated sodium channel Nav1.7.
Williams BS; Felix JP; Priest BT; Brochu RM; Dai K; Hoyt SB; London C; Tang YS; Duffy JL; Parsons WH; Kaczorowski GJ; Garcia ML
Biochemistry; 2007 Dec; 46(50):14693-703. PubMed ID: 18027973
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a novel class of benzazepinone Na(v)1.7 blockers: potential treatments for neuropathic pain.
Hoyt SB; London C; Gorin D; Wyvratt MJ; Fisher MH; Abbadie C; Felix JP; Garcia ML; Li X; Lyons KA; McGowan E; MacIntyre DE; Martin WJ; Priest BT; Ritter A; Smith MM; Warren VA; Williams BS; Kaczorowski GJ; Parsons WH
Bioorg Med Chem Lett; 2007 Aug; 17(16):4630-4. PubMed ID: 17588748
[TBL] [Abstract][Full Text] [Related]
18. Imidazopyridines: a novel class of hNav1.7 channel blockers.
London C; Hoyt SB; Parsons WH; Williams BS; Warren VA; Tschirret-Guth R; Smith MM; Priest BT; McGowan E; Martin WJ; Lyons KA; Li X; Karanam BV; Jochnowitz N; Garcia ML; Felix JP; Dean B; Abbadie C; Kaczorowski GJ; Duffy JL
Bioorg Med Chem Lett; 2008 Mar; 18(5):1696-701. PubMed ID: 18243692
[TBL] [Abstract][Full Text] [Related]
19. Sodium channel activators: model of binding inside the pore and a possible mechanism of action.
Tikhonov DB; Zhorov BS
FEBS Lett; 2005 Aug; 579(20):4207-12. PubMed ID: 16083886
[TBL] [Abstract][Full Text] [Related]
20. 3-Amino-1,5-benzodiazepinones: potent, state-dependent sodium channel blockers with anti-epileptic activity.
Hoyt SB; London C; Wyvratt MJ; Fisher MH; Cashen DE; Felix JP; Garcia ML; Li X; Lyons KA; Euan MacIntyre D; Martin WJ; Priest BT; Smith MM; Warren VA; Williams BS; Kaczorowski GJ; Parsons WH
Bioorg Med Chem Lett; 2008 Mar; 18(6):1963-6. PubMed ID: 18289851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
